https://www.selleckchem.com/pr....oducts/RO4929097.htm
However, of 77 children with at least one follow up, five children 6.54% (95% CI 2.1-14.5) experienced LVEF reduction of 10%, though not to a final value of 50%. No deterioration of systolic function was found among 20 children who completed follow-up (F=2.43, p-value=.07). In this cohort of patients, most received a low cumulative doxorubicin dose and only 22% were available for evaluation at study end; no cardiotoxic events associated with doxorubicin administration were observed after 12months. In this cohort of patients, m
Like
Comment
Share
